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Background. Risk factors for acquired rifampicin resistance (ARR) in human immunodeficiency virus (HIV)/
tuberculosis coinfection, in the highly active antiretroviral therapy (HAART) era, needs evaluation. We studied the
impact of HIV and HAART on ARR among patients taking thrice-weekly antituberculosis therapy.
Methods. This cross-protocol analysis included patients with newly diagnosed, rifampicin-susceptible pulmo-
nary tuberculosis, with and without HIV, enrolled in clinical trials (who took >80% of medication) at the National
Institute for Research in Tuberculosis between 1999 and 2013. All patients received rifampicin and isoniazid for 6
months reinforced with pyrazinamide and ethambutol in the first 2 months, given thrice-weekly throughout the
study along with HAART in one of the groups. Outcomes were categorized and multivariate logistic regression anal-
ysis performed to identify risk factors for ARR.
Results. The per-protocol results included patients with tuberculosis: 246 HIV-uninfected patients (HIV–TB+),
212 HIV patients not on HAART (non-HAART), and 116 HIV-infected patients on HAART. Median CD4 counts of
the latter 2 groups were 150 and 93 cells/µL, respectively, and the median viral loads were 147 000 and 266 000 cop-
ies/mL, respectively. Compared with HIV–TB+, the relative risks (RRs) for an unfavorable response in the coinfected,
non-HAART and HAART groups were 2.1 (95% confidence interval [CI], 1.7–14.8; P < .0001) and 2.1 (95% CI,
.9–5.2; P = .3), whereas for ARR, the RRs were 21.1 (95% CI, 2.6–184; P < .001) and 8.2 (95% CI, .6–104; P = .07),
respectively.
Conclusions. HIV-infected patients with tuberculosis treated with a thrice-weekly antituberculosis regimen are
at a higher risk of ARR, compared with HIV-uninfected patients, in the presence of baseline isoniazid resistance.
HAART reduces but does not eliminate the risk of ARR.
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Human immunodeficiency virus (HIV) and tuberculo-
sis coinfection continues to be a global health problem,
complicated further by emergence of drug resistance
[1]. Despite drug–drug interactions, the ability of
rifampicin to destroy intracellular and intermittently
growingMycobacterium tuberculosis makes it indispen-
sible in the treatment of HIV-associated tuberculosis
[2]. Non-rifampicin-containing regimens have shown
inferior cure rates [3].
A unique phenomenon complicating management of
HIV-associated tuberculosis despite supervised therapy
is the emergence of acquired rifampicin resistance
(ARR). ARR has been reported with the use of once-,
twice-, and thrice-weekly administered rifamycins in
the pre–highly active antiretroviral therapy (HAART)
era [4–6]. ARR in HIV-negative tuberculosis is infre-
quent [4, 7].
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In India, the Revised National Tuberculosis Control Program
(RNTCP) recommends a fully intermittent thrice-weekly anti-
tuberculosis treatment (ATT) regardless of HIV status [8]. The
efficacy of this thrice-weekly ATT regimen in HIV-uninfected
patients with tuberculosis treated under trial conditions was
found to be 96% among new smear-positive cases [9].The effec-
tiveness of the same intermittent regimen was 74% under field
conditions [10]. Vashishtha et al found no differences between
HIV-infected and -uninfected patients with respect to tuber-
culosis failures or relapses, using the RNTCP regimen [10].
However, a recent meta-analysis favored a daily instead of an
intermittent ATT regimen, in the context of HIV [11]. Current
World Health Organization (WHO) guidelines recommend
daily treatment, at least in the intensive phase, for HIV-coinfected
tuberculosis patients. However, supporting evidence from ran-
domized controlled clinical trials (RCTs) for the shift to a daily
regimen is lacking [12].
We performed a cross-protocol analysis, comparing 3 dis-
tinctive cohorts of patients with newly diagnosed pulmonary
tuberculosis: (1) those who were HIV uninfected; (2) those
who were HIV infected and not on HAART; and (3) those
who were HIV infected and on HAART. All patients were
being treated with an identical thrice-weekly ATT regimen
given for 6 months. This enabled us to evaluate the influence
of HIV and the role of HAART in preventing ARR.
SUBJECTS AND METHODS
Study Cohorts
The present analysis used data collected from patients with
newly diagnosed pulmonary tuberculosis patients enrolled in
4 RCTs. These trials were conducted at the National Institute
for Research in Tuberculosis, Chennai, India. All patients had
culture-positive pulmonary tuberculosis, with rifampicin-
susceptible isolates at baseline. Patients with >80% treatment
adherence (per-protocol results) were included in this analysis.
A double-blind RCT that evaluated the role of inhaled ste-
roids in reducing lung function impairment in pulmonary tu-
berculosis, between 1999 and 2001, enrolled HIV-uninfected
patients with tuberculosis (“HIV–TB+” group). The RCT com-
paring a fully intermittent 6- and 9-month antituberculosis reg-
imen (NCT 0376012) formed the “HIV+TB+, non-HAART”
group. This study was conducted in the pre-HAART era be-
tween 2000 and 2005. The 9-month regimen in this trial was
essentially identical to the 6-month regimen but with an addi-
tional 3 months of continuation phase. Hence, analysis was
done by combining the 2 regimens, but restricting the observa-
tions to the first 6 months in the longer regimen [6]. The third
group consisted of patients enrolled in 2 trials (NCT 00332306
and NCT0933790), receiving the same regimen of intermittent
ATT along with efavirenz-based HAART (“HIV+TB+HAART”
group). The first trial comparing efficacy and safety of once-
daily nevirapine and efavirenz–based antiretroviral therapy
(ART) in HIV-associated tuberculosis (NCT 00332306) [13]
enrolled HIV-infected patients with tuberculosis between
2006 and 2008. The second trial (NCT 0933790) [14], compar-
ing daily vs intermittent ATT, included only patients on thrice-
weekly regimen (ongoing from 2009).
Baseline Investigations
Baseline laboratory investigations included HIV testing, hepati-
tis B and C serology, complete blood count (automated hema-
tology analyzer, ABX), liver and renal function tests, and
random plasma glucose (automated analyzer, Olympus Corpo-
ration). Estimation of CD4+ T-cell count (FACSCount flow
cytometer, Becton Dickinson), and plasma HIV RNA load
(Roche Amplicor automated viral load monitor) were done
only for HIV-infected patients.
Three sputum specimens were examined for acid-fast bacilli by
fluorescent microscopy and cultured on solid media (Lowenstein-
Jensen) every month during the entire treatment period. Two
positive cultures at baseline and all subsequent positive cultures
were subjected to species identification and drug susceptibility
testing using standard techniques [15, 16]. Chest radiographs
were taken at baseline and the second and sixth months of
ATT. Tuberculosis patients in the age group >15 years in the
HIV-uninfected cohort and >18 years in the 2 HIV-infected co-
horts were enrolled. All study subjects had to satisfy the clinical,
sociological, and laboratory eligibility criteria for enrollment.
DNA fingerprinting was performed on paired isolates from stored
cultures (at baseline and at the time of failure with bacteriological
confirmation). Three molecular methods—namely, IS6110 analy-
sis, mycobacterial interspersed repetitive unit–variable number
tandem repeat typing, and spacer oligonucleotide typing (spoligo-
typing)—were used for identification of the mycobacterial strain
on these paired isolates. The trials were individually approved by
the Institutional Ethics Committee. Written informed consent
was obtained from all study participants prior to enrollment.
Treatment Details
All tuberculosis patients were treated with a thrice-weekly inter-
mittent regimen consisting of isoniazid (INH) 600 mg and ri-
fampicin 450 mg or 600 mg (based on weight <60 or >60 kg)
for 6 months, reinforced with ethambutol 1200 mg and pyrazi-
namide 1500 mg in the first 2 months of therapy. All tubercu-
losis drugs were assayed for content as part of quality assurance.
Treatment was fully supervised in all except the NCT0376012
trial, where the continuation phase had only 1 of 3 doses super-
vised. Patients selected from the NCT0033206 study were initiated
on HAART at 2 months of ATT. The HAART regimen consisted
of didanosine (250/400 mg for body weight <60 or >60 kg), lam-
ivudine (300 mg), and efavirenz (600 mg) given once daily [13].
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Those patients, included from the NCT0933790 trial [14], had
either tenofovir (300 mg once daily) or zidovudine (300 mg
twice daily), along with lamivudine (150 mg twice daily) and
efavirenz (600 mg once daily), initiated within the first 2–8
weeks (based on prevailing ART guidelines) [17, 18]. All
HIV-infected patients were given cotrimoxazole double
strength, 1 tablet daily, if their CD4 count was <350 cells/µL,
in addition to pyridoxine 10 mg daily.
Outcome Definition
A cure or favorable response to treatment was defined as all
available cultures (6 in number) in the last 2 months of treat-
ment being negative. Unfavorable responses included failure
and death due to tuberculosis. Failure was further classified as
bacteriological when patients had at least 2 positive cultures
in the last 2 months of treatment or persistent culture positivity
after 4 months of treatment, and clinical when clinical and /or
radiographic deterioration mandated change or extension of
ATT, without accompanying positivity in sputum culture.
Statistical Analysis
Per-protocol results from the 3 groups were analyzed using
SPSS software, version 20. The χ2 and Fisher exact tests were
used for testing differences between proportions. The relative
risk for ARR and unfavorable responses was calculated taking
HIV-uninfected patients with tuberculosis as the standard,
and comparing it with the 2 HIV-infected groups with and
without HAART. A multiple logistic regression model was
used to identify factors contributing to ARR, after adjusting
for covariates. Baseline variables that were considered impor-
tant (age, sex, weight, CD4 count, HAART use, culture grade,
and INH resistance) were used to fit the regression model,
and odds ratios with 95% confidence intervals (CIs) were com-
puted. Furthermore, the backward elimination method was
used to identify the significant covariates associated with
ARR. Regression analysis was done for the whole group as
well as within the HIV-infected group separately.
RESULTS
This retrospective cross-protocol analysis included data from
246 HIV-uninfected patients with tuberculosis (HIV–TB+),
212 HIV-infected patients with tuberculosis not on HAART
(HIV+TB+, non-HAART), and 116 HIV-infected patients
with tuberculosis and on HAART (HIV+TB+HAART). Base-
line/pretreatment characteristics of the 3 groups, including
their drug susceptibility patterns, are shown in Table 1. The
bacteriologic failures among the HIV–TB+ group, HIV+TB+,
Table 1. Pretreatment (Baseline) Characteristics of Patients in the 3 Cohorts
Characteristica HIV–TB+ (n = 246) HIV+TB+, Non-HAART (n = 212) HIV+TB+HAART+ (n = 116) P Value
Age, y, mean (SD) 30 (12) 35 (8) 36 (8) <.01
Male sex, % 66 80 87 <.001
Weight, kg, mean (SD) 42.7 (6.9) 43.4 (8.3) 41.6 (7.2) .41
HIV-related parameters
Viral load, copies/mL, median (IQR) Not done 147 000 (31 800–504 000) 266 000 (71 700–750 000) <.001
CD4 count, cells/µL, median (IQR) Not done 150 (82–283) 93 (44–158) <.001
Tuberculosis-related evaluation
Chest radiographic findings
Cavitation, % 63 16 12 <.001
Radiographic lesions ≥3 zones, % 75 19 59 <.001
Mycobacteriology (sputum)
Smear positive for AFB, % 99 76 85 <.001
Culture grading 2+ or higher, % 91 57 65 <.001
Susceptible to all first-line drugs, No. (%) 224 (90) 182 (88) 106 (91)
Isoniazid resistance, No. (%) 12 (5) 10 (5) 5 (5)
Streptomycin resistance, No. 6 3 3
S/H resistance, No. 3 9 0
S/H/E resistance, No. 0 2 0
Sensitivity unavailable, No.b 0 6 2
Overall isoniazid resistance, No. (%) 15 (6) 21 (10) 5 (5) .12
Abbreviations: AFB, acid-fast bacilli; E, ethambutol; H, isoniazid; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile
range; S, streptomycin; SD, standard deviation; TB, tuberculosis.
a Among patients with culture-confirmed, rifampicin-sensitive pulmonary tuberculosis at enrollment.
b Sensitivity could not be set as they had a colony growth of <10 or culture was contaminated.
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non-HAART group, and HIV+TB+HAART group were 4% (9/
246), 9% (19/212), and 5% (6/116), respectively. Details of tu-
berculosis treatment outcomes are provided in Table 2.
In addition, 4 patients (3 with lesions in the brain and 1 with
clinical and radiological deterioration in the chest radiograph)
in the HIV+TB+, non-HAART group as well as 1 patient
(who developed an open pneumothorax) in the HIV+TB+-
HAART group, were classified as clinical failures, as their clin-
ical condition necessitated extension of treatment beyond 6
months. None of the patients in the HIV-uninfected group re-
quired ATT extension beyond 6 months.
Compared with the HIV-uninfected group, the relative risk of
an unfavorable response was 5.1 (95% CI, 1.7–14.8; P = .00009)
in the HIV+TB+, non-HAART group and 2.12 (95% CI, .9–5.2;
P = .3) in the HIV+TB+HAART group (Table 2). Among HIV-
infected patients, the relative risk for unfavorable response was
2.4 times more (95% CI, 1.2–4.7; P = .0045) in the absence of
HAART. The sputum culture negativity by month in the 3
groups is depicted in Figure 1.
Comparison of the drug susceptibility pattern among bacter-
iologically confirmed cases, at pretreatment and at failure, in
each of the groups is provided in Table 3. All 19 patients who
Table 2. Tuberculosis Treatment Outcome in the 3 Groups
Outcome HIV–TB+ (n = 246) HIV+TB+, Non-HAART (n = 212) HIV+TB+HAART+ (n = 116)
Cured, No. (%) 237 (96) 174 (82) 107 (92)
Unfavorable, No. (%) 9 38 9
Bacteriologic failure 9 (4) 19 (9) 6 (5)
Clinical failure 0 4 1
Deaths 0 15 2
ARR among failures, No. (%) 1/9 (11) 19/19 (100) 4/6 (67)
RR for unfavorable responses (95% CI) 1 5.1 (1.7–14.8); P< .0001 2.1 (.9–5.2); P= .3
RR for ARR (95% CI) 1 21.1 (2.6–184); P< .001 8.2 (.6–104); P= .07
Abbreviations: ARR, acquired rifampicin resistance; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; RR,
relative risk; TB, tuberculosis.
Figure 1. Proportion (%) of patients with tuberculosis (rifampicin-susceptible strain at baseline) becoming culture negative during the course of antitu-
berculosis treatment (ATT), by month, in the 3 groups. Abbreviations: HIV−TB+, human immunodeficiency virus uninfected, tuberculosis infected; HIV+TB+,
non-HAART, human immunodeficiency virus infected, tuberculosis infected, not on highly active antiretroviral therapy; HIV+TB+HAART, human immunode-
ficiency virus infected, tuberculosis infected, on highly active antiretroviral therapy; HIV−TB+HAART, human immunodeficiency virus uninfected, tuberculosis
infected, on highly active antiretroviral therapy.
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failed therapy in the HIV+TB+, non-HAART group had
emergence of ARR. Fifteen of the 19 patients developed multi-
drug-resistant tuberculosis (resistance to both isoniazid and ri-
fampicin), with 4 developing rifampicin monoresistance. Three
of the 6 bacteriological failures in the HIV+TB+HAART group
and 1 of the 9 failures in the HIV–TB+ group had emergence of
ARR. The relative risk of ARR was 21.1 (95% CI, 2.6–184;
P < .001) and 8.2 (95% CI, .6–104; P = .07) when the HIV+
TB+, non-HAART group and the HIV+TB+HAART group
were compared with the HIV–TB+ group. Analysis within the
HIV group showed that the risk of ARR was 2.6 (95% CI,
.90–7.4; P = .06) in the absence of HAART.
Multiple logistic regression analysis showed that INH resis-
tance and HIV infection were significant risk factors for ARR.
When logistic regression was restricted to HIV-infected pa-
tients, INH resistance was found to be a highly significant risk
factor, along with lower CD4 count and higher sputum culture
grade at baseline (Table 4). DNA fingerprinting was available
for 18 of 25 paired isolates (comprising 15 of 19 failures in
the HIV+TB+, non-HAART group and 3 of 6 in the HIV+TB+-
HAART group), and confirmed that 78% (14/18) of bac-
teriological failures were due to the same strain. Four failures
(4/18) in the HIV+TB+, non-HAART group were caused by a
different strain of M. tuberculosis.
DISCUSSION
This unique comparison of tuberculosis treatment outcomes
from 3 different groups of patients, treated with an identical
thrice-weekly ATT in the same setting, enabled us to evaluate
the impact of HIV and HAART on ARR. Failures during treat-
ment truly reflected the strength of the regimen rather than re-
currences, which could be influenced by tuberculosis
endemicity in that region and the level of immunodeficiency
in the patient [19, 20]. We found that failing tuberculosis
treatment and speed of culture conversion were relatively simi-
lar in HIV–TB+ and HIV+TB+HAART patients, despite ad-
vanced immunodeficiency in the latter group (Figure 1). The
advanced stage of HIV in the HIV+TB+HAART group (higher
viral load and lower CD4 count), with possibly prolonged peri-
od of immunodeficiency, could explain why HAART initiation
did not completely offset the tendency for emergence of ARR,
even though it significantly improved overall tuberculosis out-
comes. Hence, the WHO recommendation for early and con-
comitant initiation of HAART for all HIV-infected patients
with tuberculosis irrespective of CD4 counts, while reducing
treatment failures, may not fully protect against emergence of
ARR [18].
Table 3. Drug Susceptibility Pattern at Baseline and at the Time of Failure Among Patients With Bacteriologically Confirmed Failure
Susceptibility Pattern
HIV–TB+(n = 9)
HIV+TB+, Non-HAART
(n = 19) HIV+TB+HAART (n = 6)
Baseline Failure Baseline Failure Baseline Failure
Susceptible to all first-line drugs 6 3 9 0 4 2
Isoniazid monoresistance 3 5 5 0 2 0
Resistant to S/H 0 0 4 0 0 0
Resistant to S/H/E 0 0 1 0 0 0
Rifampicin monoresistance 0 0 0 4 0 1
Multidrug resistance (H/R) 0 1 0 15 0 3
% of ARR among failures 11 100 67
Abbreviations: ARR, acquired rifampicin resistance; E, ethambutol; H, isoniazid; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; R,
rifampicin; S, streptomycin; TB, tuberculosis.
Table 4. Multiple Logistic Regression Analysis to Identify Baseline
Risk Factors for Acquired Rifampicin Resistance Among Patients
With Tuberculosis on Thrice-Weekly Antituberculosis Therapy
Baseline Risk Factors P Value OR 95% CI
Among the 3 cohorts
Sex .21 0.53 .19–1.44
Age .20 1.03 .95–1.06
Resistance to INH . . . 9.97 3.43–28.37
Weight .17 0.95 .91–1.03
Sputum culture grade .34 1.31 .88–2.55
HIV infected .01 2.02 1.58–16.77
Among HIV-coinfected patients
Sex .12 0.42 .14–1.26
Age .69 0.99 .92–1.06
Resistance to INH . . . 13.28 4.25–41.37
Weight .52 0.98 .92–1.05
Sputum culture grade .03 2.00 1.01–3.70
On HAART .08 2.68 .88–8.1
CD4 count at nadir .03 0.98 .97–.99
Abbreviations: CI, confidence interval; HAART, highly active antiretroviral
therapy; HIV, human immunodeficiency virus; INH, isoniazid; OR, odds ratio.
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Pretreatment INH resistance is a known risk factor for ampli-
fication of drug resistance among tuberculosis patients on ATT
[21]. In fact, the incidence of ARR, even among HIV-uninfected
patients with tuberculosis, was 5 times higher in the presence of
initial INH resistance compared with patients harboring fully
drug-susceptible organisms [7].
Varying plasma levels of INH and rifampicin, due to differ-
ential half-lives, cause functional monotherapy. Malabsorption
of ATT drugs in HIV may further potentiate occurrence of ARR
[22–24].Our study similarly revealed that pretreatment INH re-
sistance was a significant risk factor for development of ARR
among tuberculosis patients, irrespective of HIV status. Among
HIV-infected patients with tuberculosis, a low CD4 count and a
higher mycobacterial burden at baseline were additional risk
factors. It would be interesting to study the occurrence of
ARR among HIV patients on HAART, with a relatively higher
CD4 count at the time of tuberculosis diagnosis, as well as
among those receiving daily ATT.
Incidence of ARR was observed to be high among failures
and relapses when intermittent tuberculosis therapy was used
in the presence of HIV infection. In our previous study, all
patients who failed therapy had ARR [6]. Further, subgroup
analysis revealed that patients who developed ARR had a signif-
icantly lower CD4 cell count, lymphocyte percentage, and high-
er sputum culture grade at baseline, compared with those who
did not [6, 25]. In the study by Vernon et al, 4 of 5 patients who
relapsed in the once-weekly rifapentine arm compared with
none in the twice-weekly rifampicin arm (given in the contin-
uation phase along with INH), developed ARR [4]. Risk factors
identified included younger age, lower CD4 count, extrapulmo-
nary tuberculosis, and concomitant antifungal treatment. Of
note, none of the HIV-uninfected patients enrolled in that
trial developed ARR [4].
Additionally, in a study of 169 patients with advanced HIV,
Burman et al [24] found that 8 of 9 patients (with CD4 count
<100 cells/µL) with failure or relapse had ARR. A recent retro-
spective survey from a California tuberculosis registry reported
a 5 times higher risk of ARR in dual infection. Cavitation at
baseline and absence of directly observed therapy were other
risk factors in that study [26].
Nosocomial transmission facilitated by prolonged or fre-
quent hospitalization, which is inevitable without HAART,
could partly explain the higher rates of ARR in our HIV+TB+,
non-HAART group [6, 20, 24, 27].
Li et al [28] found that patients relapsed with ARR when in-
termittent dosing of tuberculosis drugs was used throughout the
treatment period. However, ARR was infrequent when a daily
intensive phase was followed by an intermittent continuation
phase. In a meta-analysis of published studies, Lew et al [29]
identified initial drug resistance as the main predisposing factor
for ARR. The incidence of ARR was 0.8%, 6%, and 14% when
patients harbored pan-susceptible, single-drug resistant, and
polydrug-resistant organisms, respectively [29].
Another meta-analysis among dually infected patients by
Khan et al [30] concluded that thrice-weekly antituberculosis reg-
imens were associated with more failures, relapses, and acquisi-
tion of drug resistance (to tuberculosis). This trend was reduced
considerably with HAART administration. They also found that
a daily administration of ATT during the intensive phase, with
rifampicin given throughout for at least 6 months, improved tu-
berculosis treatment outcomes in HIV-infected patients [30].
Preliminary results from an ongoing RCT comparing daily
with intermittent antituberculosis regimens in patients with
culture-positive pulmonary tuberculosis (NCT0933790) re-
vealed a significantly higher rate of culture conversion at 2
months, as well as a trend toward lower incidence of ARR in
the daily arm [14, 31].
The strengths of our study were that all patients had identical
tuberculosis regimens. Quality-assured drugs were used and
patients were treated under similar trial conditions. High com-
pliance rate and intense clinical monitoring was ensured. Myco-
bacterial culture and drug susceptibility testing were performed
every month at a supranational reference laboratory.
The limitations were that these were not head-to-head com-
parisons, but rather nonconcurrent trials. The numbers eligible
for this analysis from the HIV+TB+HAART group were relative-
ly small. Other limitations were the differences in drug super-
vision patterns and the varying time of ART initiation within
the HIV cohorts.
In conclusion, HIV-infected patients with tuberculosis are at
a higher risk of ARR than are HIV-uninfected patients, when
treated with a thrice-weekly antituberculosis regimen, especially
in the presence of baseline INH resistance. HAART reduces but
does not eliminate the risk of ARR completely. Daily tuberculo-
sis treatment, prompt diagnosis of HIV, and earlier HAART
initiation preserving immune function in HIV-infected tuber-
culosis patients could potentially prevent amplification of
drug resistance.
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